Product nameAnti-KAT4 / TBP Associated Factor 1 antibody
See all KAT4 / TBP Associated Factor 1 primary antibodies
DescriptionRabbit polyclonal to KAT4 / TBP Associated Factor 1
Tested applicationsSuitable for: IP, WB, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human KAT4/ TBP Associated Factor 1 aa 1750-1800. The exact sequence is proprietary. NP_620278.1
Database link: P21675
- WB: HEK-293T, jurkat and HeLa whole cell lysate. IP: HeLa whole cell lysate. IHC-P: Human colon cancer tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab245602 was affinity purified using an epitope specific to KAT4 immobilized on solid support.
Our Abpromise guarantee covers the use of ab245602 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
|WB||1/500 - 1/2500. Predicted molecular weight: 213 kDa.|
|IHC-P||1/500 - 1/2000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionLargest component and core scaffold of the TFIID basal transcription factor complex. Contains novel N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or transphosphorylate other transcription factors. Phosphorylates TP53 on 'Thr-55' which leads to MDM2-mediated degradation of TP53. Phosphorylates GTF2A1 and GTF2F1 on Ser residues. Possesses DNA-binding activity. Essential for progression of the G1 phase of the cell cycle.
Involvement in diseaseDefects in TAF1 are the cause of dystonia type 3 (DYT3) [MIM:314250]; also called X-linked dystonia-parkinsonism (XDP). DYT3 is a X-linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. Its prevalence is high in the Philippines. DYT3 has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease.
Sequence similaritiesBelongs to the TAF1 family.
Contains 2 bromo domains.
Contains 1 HMG box DNA-binding domain.
Contains 2 protein kinase domains.
modificationsPhosphorylated by casein kinase II in vitro.
- Information by UniProt
- BA2R antibody
- CCG1 antibody
- CCGS antibody
KAT4 / TBP Associated Factor 1 was immunoprecipitated from HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (1 mg for IP, 20% of IP loaded) using ab245602 at 6 μg/mg lysate. Western blot was perfromed on the immunoprecipitate using ab245602 at 1 μg/ml.
Lane 1: ab245602 IP in HEK-293T whole cell lysate.
Lane 2: Control IgG in HEK-293T whole cell lysate.
Detection: Chemiluminescence with an exposure time of 3 minutes.
All lanes : Anti-KAT4 / TBP Associated Factor 1 antibody (ab245602) at 0.4 µg/ml
Lane 1 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 50 µg
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 15 µg
Lane 3 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate at 50 µg
Lane 4 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 213 kDa
Exposure time: 3 minutes
Formalin-fixed, paraffin-embedded human colon carcinoma tissue stained for KAT4 / TBP Associated Factor 1 using ab245602 at 1/1000 dilution in immunohistochemical analysis. DAB staining.
ab245602 has not yet been referenced specifically in any publications.